Report Highlights

Medical Tourism in the U.S.: Market Overview

Medical tourism in the United States is distinctive because it monetizes premium quality rather than price. Inbound international patients typically spend between USD 30,000 and USD 150,000 per episode, far above the cost-led packages sold in Thailand, India, or Mexico. Revenue concentrates in academic medical centers and NCI-designated cancer hospitals, which together capture the majority of the estimated USD 8.4 billion market in 2024. Facilitator fees and travel services make up the balance.

Demand is shaped by a fragmented, provider-led structure. No single operator controls inbound flows, so hospitals run their own international patient departments and contract with independent facilitators. Pricing remains difficult to compare, although the Hospital Price Transparency rule under 45 CFR Part 180 now requires hospitals to publish standard charges. That disclosure is changing how foreign patients evaluate U.S. options before booking.

Growth Drivers in U.S. Medical Tourism

Specialist capacity is the first driver. Proton therapy centers, CAR-T cell therapy programs, and robotic surgical suites concentrated at Mayo Clinic, MD Anderson Cancer Center, and Memorial Sloan Kettering Cancer Center attract patients whose home systems lack equivalent services. Several proton facilities opened after 2020, adding treatment slots faster than domestic demand absorbs them, which leaves unused capacity for international referrals. Hospitals fill that capacity through dedicated international patient departments.

Policy and wealth supply the second and third drivers. The B-2 visitor visa permits travel for medical treatment administered by a U.S. provider, and the Department of State processes these applications at consulates in Riyadh, Dubai, and Mexico City. Saudi Arabia's Health Sector Transformation Program and growing Gulf high-net-worth populations supply the paying cohort, while Latin American patients seek oncology care unavailable through domestic public systems.

Market Restraints and Entry Barriers

The Anti-Kickback Statute under 42 U.S.C. 1320a-7b is the most consequential barrier for facilitators. Paying per-referral commissions to brokers who route patients into hospitals that bill federal programs exposes both parties to criminal liability, so compensation must be structured as flat fees. Joint Commission International accreditation, which requires substantial documentation and survey cycles, adds cost and time that smaller hospitals struggle to absorb.

Incumbent advantage and payment friction compound the problem. Academic centers already hold referral relationships with Gulf and Latin American ministries and embassies, leaving new entrants to compete for second-tier cases. Foreign patients also face visa interview backlogs at consulates, and international payment settlement often requires escrow arrangements that most U.S. providers have not built into billing systems.

Market Opportunities in the United States

Proton and CAR-T packaging for Gulf patients offers the clearest near-term entry point. Analyst estimates place inbound oncology spend at roughly USD 2.3 billion in 2024, with Saudi Arabia and the UAE supplying the largest cohorts. A facilitator that bundles visa letters, interpreter services, and hotel coordination around a single proton course can capture the travel margin that hospitals leave untouched.

Mid-tier hospitals in Florida and Texas present a second opening for orthopedic joint replacement and bariatric surgery, where U.S. prices sit closer to regional alternatives than to premium academic centers. Analyst estimates place this segment near USD 1.1 billion. Entrants that secure Joint Commission International accreditation before 2027 can market directly to Canadian and Latin American patients seeking shorter waits than public systems provide.

Market at a Glance

Leading Market Participants

• Cleveland Clinic
• Mayo Clinic
• Johns Hopkins Medicine
• MD Anderson Cancer Center
• Memorial Sloan Kettering Cancer Center
• Cedars-Sinai Medical Center
• Mount Sinai Health System
• HCA Healthcare
• Houston Methodist Hospital
• Patients Beyond Borders

Regulatory and Policy Environment

The Hospital Price Transparency rule at 45 CFR Part 180 requires hospitals to publish standard charges in machine-readable files, with CMS enforcing through civil monetary penalties. The Anti-Kickback Statute governs facilitator compensation, while HIPAA under 45 CFR Parts 160 and 164 governs patient data handled by international coordinators. EMTALA obliges emergency departments to screen every patient regardless of nationality or ability to pay.

Visa rules sit with the Department of State, which issues B-2 visas under the Immigration and Nationality Act, and processing timelines vary sharply by consulate. Joint Commission International accreditation surveys typically run over several months before certification. Federal subsidies for inbound patients are absent, but Texas and Florida offer economic development incentives to hospitals expanding specialist capacity, with the Texas Enterprise Fund a recognized mechanism.

Long-Term Outlook for U.S. Medical Tourism

By 2032 the U.S. market will be defined by specialist concentration rather than volume growth. Revenue should reach USD 14.6 billion as oncology, cardiac, and cell therapy packages scale at flagship centers in Houston, Rochester, and New York. Pricing transparency will narrow the information gap, rewarding providers that publish outcomes alongside standard charges. Patient counts will stay concentrated among high-income origin markets.

Competition will tighten as Gulf governments reduce outbound referrals by building domestic proton and transplant capacity. Facilitators that survive will hold accreditation, transparent fee structures, and direct hospital contracts rather than commission-based brokerage. Investors entering now should expect consolidation among facilitators by 2030 and selective hospital acquisitions in Florida and Texas.